KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Long-Term Debt Issuances (2016 - 2021)

Historic Long-Term Debt Issuances for Vertex Pharmaceuticals (VRTX) over the last 8 years, with Q4 2021 value amounting to $10.0 million.

  • Vertex Pharmaceuticals' Long-Term Debt Issuances rose 11468.44% to $10.0 million in Q4 2021 from the same period last year, while for Sep 2022 it was $10.0 million, marking a year-over-year decrease of 4205.59%. This contributed to the annual value of $22.6 million for FY2021, which is 6992.48% up from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Long-Term Debt Issuances stood at $10.0 million for Q4 2021, which was up 11468.44% from $1.0 million recorded in Q3 2021.
  • In the past 5 years, Vertex Pharmaceuticals' Long-Term Debt Issuances registered a high of $30.0 million during Q4 2017, and its lowest value of $1.0 million during Q3 2021.
  • Its 5-year average for Long-Term Debt Issuances is $7.2 million, with a median of $5.3 million in 2017.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Long-Term Debt Issuances skyrocketed by 13152.71% in 2017, and later tumbled by 7378.03% in 2018.
  • Vertex Pharmaceuticals' Long-Term Debt Issuances (Quarter) stood at $30.0 million in 2017, then crashed by 73.78% to $7.9 million in 2018, then rose by 14.52% to $9.0 million in 2019, then plummeted by 48.23% to $4.7 million in 2020, then soared by 114.68% to $10.0 million in 2021.
  • Its last three reported values are $10.0 million in Q4 2021, $1.0 million for Q3 2021, and $8.0 million during Q2 2021.